KPV vs LL-37: The Two Peptides Quietly Replacing Topical Steroids

LL-37 is the only antimicrobial peptide the human body dedicates specifically to defending skin. In eczema, the skin stops making it. In psoriasis, the skin makes too much of it, and a 2024 study in the Journal of Clinical Investigation found that excess is physically reshaping LDL particles and accelerating cardiovascular disease in affected patients. That split defines this comparison more than any mechanism chart. These are not two peptides doing the same job through different pathways. They solve opposite problems, and using the wrong one for your skin condition is not just ineffective; in at least one documented scenario, it causes measurable harm.

KPV (Lys-Pro-Val) is a tripeptide fragment cleaved from the C-terminus of alpha-MSH (alpha-melanocyte stimulating hormone). In healthy skin, alpha-MSH plays a central role in limiting the inflammatory cascade after UV exposure or pathogen contact. KPV carries the anti-inflammatory signal of the parent hormone in a smaller, more deliverable package. LL-37 is the active peptide form of the cathelicidin precursor hCAP-18, produced by keratinocytes, neutrophils, and sweat glands. Where KPV's job is to suppress cytokine storms, LL-37's job is to kill pathogens and signal the immune system to respond correctly to damage.

Both are being explored as alternatives to topical corticosteroids, which suppress inflammation effectively but at a cost: skin atrophy with long-term use, HPA axis suppression in children, and no effect on the underlying defense deficit that keeps eczema patients cycling through flares. Neither peptide thins skin. Neither suppresses adrenal function. But the comparison stops there, because their mechanisms and risk profiles are genuinely different.

What does LL-37 actually do in inflamed skin?

The paradox of LL-37 in dermatology is that it is simultaneously deficient in one of the most common chronic skin conditions and overactive in another, and the consequences of that overactivity are more serious than most peptide content acknowledges.

In atopic dermatitis, LL-37 production is chronically suppressed. A 2023 paper in PMC10326740 confirmed that of all antimicrobial peptides, LL-37 loss is uniquely characteristic of atopic dermatitis, unlike other inflammatory skin conditions where antimicrobial peptide levels remain normal or elevated. The mechanism involves IL-4 and IL-13, the cytokines that dominate Th2-skewed immune responses in eczema. These cytokines actively inhibit cathelicidin production in keratinocytes. The result is a skin surface that is simultaneously inflamed and defenseless, which explains why eczema patients are so disproportionately colonized by Staphylococcus aureus, a bacteria that LL-37 would normally suppress.

In psoriasis, the picture inverts. LL-37 is chronically overexpressed, and here the findings become alarming. In psoriatic skin, LL-37 binds to self-DNA released from dead keratinocytes, forming complexes that activate plasmacytoid dendritic cells via TLR9. This converts the body's own dead skin cells into autoimmune triggers, driving the type I interferon cascade that sustains psoriatic plaques. The autoimmune trigger mechanism is well established. What was less understood until recently is what LL-37 overexpression does outside the skin.

LL-37 directly remodeled LDL particles from approximately 264 angstroms to 332 angstroms in diameter, enhancing macrophage LDL uptake via LDLR, SR-B1, and CD36 receptors. Transgenic mice expressing human LL-37 developed significantly larger atherosclerotic plaques. The minimum effective concentration was 78 nM. Mouse cathelicidin (CRAMP) showed none of this activity, indicating a human-specific cardiovascular liability.

Nakamura et al., Journal of Clinical Investigation, 2024

This finding is not widely discussed in peptide communities yet. If you have psoriasis and are considering topical LL-37 because you have read it is a skin defense peptide, you need to know this first. Chronically elevated LL-37 is not a neutral bystander in psoriatic inflammation: it is now documented to drive cardiovascular comorbidity by a mechanism that is unique to the human version of the molecule. Psoriasis already carries elevated cardiovascular risk independent of traditional risk factors. Adding exogenous LL-37 to a patient who already overproduces it addresses the wrong variable entirely.

The LL-37 wound healing data tells a similarly complex story. The only published randomized controlled trial, Miranda et al. in Archives of Dermatological Research, 2023 (NCT04098562, N=25), showed topical LL-37 cream achieved 100 percent granulation tissue coverage by day 14 versus day 28 in the placebo group in diabetic foot ulcers. That headline result looks strong. But inflammatory markers including IL-1 alpha and TNF-alpha showed no significant difference between groups. The peptide accelerated tissue quality without measurably reducing the inflammatory signal. A Phase IIb trial in venous leg ulcers (N=149) found no benefit in the overall population, but a post-hoc subgroup of large ulcers (at least 10 cm squared) showed 28.1 percent closure with 0.5 mg/mL LL-37 versus 8.1 percent with placebo. In the same trial, the higher dose of 1.6 mg/mL performed worse than the lower dose. That dose inversion has no settled explanation and suggests the therapeutic window is narrow.

How KPV works, and why the MC1R assumption is wrong

Most explanations of KPV start with MC1R, the melanocortin-1 receptor that the parent hormone alpha-MSH binds to regulate skin pigmentation and inflammation. The inference is that KPV, being a fragment of alpha-MSH, works through the same receptor. This is incorrect, and the distinction matters clinically.

KPV enters cells primarily through PepT1, a proton-coupled peptide transporter expressed on the surface of intestinal epithelial cells, keratinocytes, and immune cells. Once inside, it suppresses NF-kB and MAPK signaling pathways independently of any receptor binding. A 2025 study in Tissue and Cell confirmed this mechanism in human HaCaT keratinocytes exposed to PM10 particulate stress: KPV at 50 micrograms per milliliter restored cell viability, reduced IL-1 beta secretion, and suppressed apoptosis markers including Bax and cleaved caspase-3, with effects mediated through NF-kB suppression and verified in a 3D skin model.

The practical implication is significant. MC1R loss-of-function variants, including the Arg151Cys, Arg160Trp, and Asp294His substitutions common in fair-skinned and red-haired individuals, are associated with increased UV sensitivity and a higher baseline inflammatory tone in skin. These individuals might reasonably assume their broken melanocortin signaling would limit their response to alpha-MSH-derived peptides. With KPV, it does not. The PepT1-mediated, receptor-independent mechanism means MC1R variants have no meaningful effect on KPV's anti-inflammatory activity. People with the highest UV-inflammatory burden, who often carry these variants, can expect the full effect.

There are no published human clinical trials of KPV for skin conditions as of May 2026. The evidence base is preclinical: keratinocyte cell lines, rodent wound models, and colitis mouse studies. A 2024 paper in Frontiers in Pharmacology (Zhang et al.) showed a KPV and FK506 co-assembled nanodrug achieved 80 percent survival versus 60 percent untreated in acute DSS colitis mice, with full tight junction restoration. The intestinal data is more extensive than the skin data, but the NF-kB suppression mechanism is shared. Transdermal delivery remains a formulation challenge: passive diffusion delivers undetectable amounts, while a 2017 study in the Journal of Pharmaceutical Sciences found iontophoresis combined with microneedle pretreatment increased skin permeation 35-fold, which explains why microneedle-assisted topical formulations are the current clinical preference.

How do KPV and LL-37 compare directly?

What the wound healing dose paradox tells you

The Phase IIb venous leg ulcer trial result deserves more attention than it gets. In the trial (N=149), the 0.5 mg/mL dose of LL-37 outperformed the 1.6 mg/mL dose in the subgroup that responded at all. The lower dose produced 28.1 percent wound closure versus 8.1 percent placebo. The higher dose did not improve on placebo. A peptide that performs better at lower concentration in a wound environment fits the known biology: LL-37 at elevated local concentrations activates mast cells and drives pro-inflammatory degranulation via TLR2 and JAK2/STAT3. Below a certain threshold, the antimicrobial and pro-healing signals dominate. Above it, the inflammatory signals take over. This is not a problem that dose escalation solves. It is an argument for precise, low-dose formulations and against the assumption that more peptide means better results.

How your genes determine which of these works for your skin

The FLG genetics question is the most clinically relevant genetic angle in the atopic dermatitis space, and it is almost entirely absent from peptide content. FLG encodes filaggrin, the protein that bundles keratin filaments in the outermost layers of skin and is the primary structural component of the skin barrier. Loss-of-function mutations in FLG are present in 14 to 42 percent of atopic dermatitis patients across European and Asian populations. They are the single largest genetic risk factor for the condition identified to date.

The connection to LL-37 is mechanistic. FLG-null keratinocytes produce less natural moisturizing factor, which raises transepidermal water loss and shifts the immune environment toward Th2 dominance. IL-4 and IL-13, the core Th2 cytokines, directly suppress cathelicidin expression in keratinocytes. So FLG-null patients are not just predisposed to eczema through barrier dysfunction: they are also predisposed to chronically low LL-37 through the downstream immune skew the barrier failure causes. The barrier breaks down, the immune system shifts Th2, the Th2 environment suppresses the defense peptide, S. aureus colonizes the undefended surface, and the colonization worsens the inflammation. Supplementing LL-37 in this specific population targets a genuine molecular gap.

For KPV and MC1R, the relevant finding is what does not happen. In the melanocortin signaling literature, the anti-inflammatory effects of alpha-MSH in skin are mediated through MC1R and MC3R. The assumption has been that peptide fragments of alpha-MSH would require the same receptors. Research on KPV's mechanism clarified this: the PepT1 uptake pathway operates independently of MC1R. The anti-inflammatory effect of KPV in studies of keratinocyte cytokine production was maintained in MC1R-independent conditions. For someone carrying MC1R Arg151Cys (the most common loss-of-function variant in European populations, found in up to 10 percent of fair-skinned individuals), KPV is the more reliable choice precisely because it does not depend on the receptor that is compromised. See the full skin peptide guide for how other skin peptides interact with melanocortin variants.

The practical guide for genetic interpretation: if you have confirmed FLG null status, LL-37 addresses the most upstream molecular deficit in your eczema. If your eczema is moderate to severe, involving significant S. aureus burden, and not driven by psoriatic or rosacea-type overexpression, LL-37 is the more targeted choice for the defense layer. KPV is appropriate alongside it or as the primary anti-inflammatory when pathogen load is not the driver. If you have psoriasis risk variants, avoid LL-37 entirely and use KPV for its NF-kB suppression profile. The DNA-first decision framework walks through how to read your inflammatory genotype before choosing any anti-inflammatory peptide protocol. For broader context on skin healing peptides and what the evidence shows for each, the peptide healing guide covers BPC-157, GHK-Cu, and the tissue repair stack alongside the skin-specific options discussed here.

Can you actually get KPV or LL-37 in 2026?

The regulatory status of both peptides changed materially in April 2026. Both KPV and LL-37 had been on the FDA's Category 2 interim bulk substances list, meaning 503A compounding pharmacies faced legal uncertainty when preparing them for patient prescriptions. On April 22, 2026, the FDA removed both from Category 2 as part of a broader review of 12 peptides (Frier Levitt, 2026; The Peptide Catalog, April 2026).

Removal from Category 2 does not mean approval. Neither peptide is on the 503A positive bulks list, and neither holds an FDA-approved indication. KPV is now formally scheduled for Pharmacy Compounding Advisory Committee (PCAC) review on July 23 to 24, 2026 (FDA.gov advisory committee calendar). A favorable PCAC recommendation would provide clearer legal standing for 503A compounders preparing KPV for wound healing and inflammatory conditions. LL-37 does not yet have a confirmed PCAC date.

503B outsourcing facilities, which operate under stricter manufacturing standards than 503A pharmacies and can produce larger batch quantities, cannot currently compound either peptide, as neither appears on the 503B bulks list (Federal Register, May 2026). For patients, this means access currently exists through 503A compounding pharmacies under physician prescription, which carries legal legitimacy post-Category 2 removal but lacks the manufacturing oversight of 503B. All current clinical use remains off-label.

The safety profile picture for LL-37 is more complex than for KPV. A 2023 murine study (PMC10136735) documented irreversible rosacea-like lesions with long-term LL-37 administration. A December 2024 review in Antibiotics (MDPI) explicitly flagged LL-37's cytotoxicity, proteolytic instability, and unresolved resistance emergence as barriers to clinical translation. No formal FDA adverse event warnings or MedWatch alerts have been issued for either peptide, but the absence of human trial data means the safety profile reflects a knowledge gap rather than a confirmed clean record. See the KPV peptide page for current formulation options and compounding pharmacy context.